Microdialysis is a technique that allows the measurement of concentrations of free antibiotic in tissue. The free antibiotic concentration is responsible for the antibacterial effect at the target site. We used microdialysis in animal and human studies to investigate the tissue penetration of cefpodoxime. In the animal study, total plasma and free muscle and lung concentrations of cefpodoxime were measured after male Wistar rats had received either 10 mg/kg or 20 mg/kg iv cefpodoxime over 5 h or a continuous iv infusion of 260 µ µ µ µg/h cefpodoxime after a loading dose of 6 mg/kg. Free muscle concentrations of cefpodoxime were similar to free lung concentrations and therefore provided a surrogate measure of cefpodoxime concentrations at the pulmonary target site. In an open, randomized, two-way crossover, single-dose study in six healthy male volunteers, total plasma and free muscle concentrations were measured after a single oral dose of cefpodoxime 400 mg or cefixime 400 mg. The total plasma concentrations of each antibiotic were similar and higher than free muscle concentrations. The tissue penetration of cefpodoxime was, however, greater than that of cefixime, as shown by two-fold higher peak free muscle concentrations after dosing with cefpodoxime than with cefixime (2.1 mg/L versus 0.9 mg/L). In addition, the area under the curve for tissue (AUC t ) of cefpodoxime (400 mg) was more than double that of cefixime (400 mg), based on free antibiotic concentrations (15.4 mg · h/L versus 7.3 mg · h/L). These findings indicate that, taking into account pharmacokinetic/pharmacodynamic considerations, cefpodoxime is likely to be more efficacious than cefixime, due to its greater tissue penetration.
Introduction
Pharmacokinetic/pharmacodynamic (PK/PD) models integrate in vitro microbiological activity data with the pharmacokinetic characteristics of an antibiotic, and are useful in predicting therapeutic efficacy. 1 For β-lactams, the PK/PD parameter that best correlates with bacteriological eradication is the time above the MIC. For optimal therapeutic efficacy, it has been proposed that dosing schedules for β-lactam antibiotics should maintain plasma antibiotic concentrations above the MIC for relevant bacterial pathogens for at least 50% of the dosing interval. 2 Plasma concentrations may not, however, be the ideal parameter on which to base antibiotic dosing schedules. Most infections occur not in plasma but in tissues, and therefore the ability of antibiotics to reach the target sites is a key determinant of clinical outcome. Free (unbound) antibiotic concentrations in the interstitial fluid are responsible for the activity of an antibiotic in important indications and may be more relevant in predicting therapeutic efficacy in, for example, pneumonia, acute exacerbations of chronic bronchitis, and infections of skin and soft tissue.
Measurement of free antibiotic concentrations in the interstitial fluid at the site of the infection can be achieved using microdialysis, which is an analytical method that permits sampling of the extracellular tissue fluid. Microdialysis is a reliable technique that has been used to investigate the kinetics of antibiotics in vivo in different tissues. 3, 4 The penetration of cefpodoxime into the interstitial fluid space was therefore investigated in animal and clinical studies using microdialysis. Cefpodoxime is an oral cephalosporin with a broad spectrum of antibacterial activity, and has proven efficacy in the treatment of community-acquired respiratory tract infections. First, an animal study was performed in which the free tissue concentrations of cefpodoxime in muscle and lung were compared to determine whether tissue concentrations in the more easily accessible muscle could be taken as a surrogate for the concentrations achieved in the lung, which is one of the target tissues for cefpodoxime. Since lung disposition studies in humans are difficult to perform, an assumption was made here that the extent of distribution of the drug to different tissues in animals and humans is comparable. The tissue penetration of cefpodoxime was then compared with that of cefixime, another oral cephalosporin with a spectrum of activity similar to that of cefpodoxime, in human volunteers. The daily dose of these two agents for the treatment of most respiratory tract infections is the same (400 mg), but they differ in the extent of plasma protein binding, which is about 25% with cefpodoxime 5 compared with 65% for cefixime, 6 which may have implications for therapeutic efficacy, due to the potentially greater concentration of cefpodoxime at the target site.
Materials and methods

Animal study
An animal study was performed using an established rat model to quantify cefpodoxime penetration into the muscle and lung. 7 The study was approved by the Institutional Animal Care and Use Committee of the University of Florida and performed at the University of Florida in accordance with good laboratory practice as well as the Principles of Laboratory Animal Care. 8 A total of 18 male Wistar rats were used; two groups of six rats each received a single iv dose of either 10 mg/kg or 20 mg/kg cefpodoxime, and the other six rats received an iv loading dose of cefpodoxime 6 mg/kg followed by continuous iv infusion of cefpodoxime 260 µg/h over a 5 h period. Microdialysis probes (CMA/20; CMA/Microdialysis AB, Stockholm, Sweden) were implanted in both muscle and lung tissue, and blood and microdialysis samples were collected at fixed time intervals. Plasma, muscle and lung concentrations were measured using a validated modified high-performance liquid chromatography assay. 9 Clinical study An open, randomized, two-way crossover, single-dose study to compare tissue penetration of cefpodoxime and cefixime by microdialysis of muscle tissue was subsequently conducted in six healthy male volunteers. The study was approved by the Ethics Committee of the University of Florida and was conducted in accordance with the Declaration of Helsinki (1964, with subsequent amendments). All subjects gave written informed consent prior to entry into the study. After routine screening examinations, subjects were randomized to a specific order of dosing with single-dose cefpodoxime proxetil 400 mg (Vantin tablets; Pharmacia, Kalamazoo, MI, USA) and cefixime 400 mg (Suprax tablets; Lederle Consumer, Philadelphia, PA, USA), with a washout period of at least 2 weeks between doses. On each study day, a plastic cannula (JELCO; Johnson-Johnson, Arlington, TX, USA) was inserted into an antecubital vein for blood sampling.
Microdialysis
Microdialysis was performed as described previously. 10 Briefly, a dialysis probe (CMA/60) was inserted into a medial vastus muscle, and the microdialysis system was then connected and perfused with lactate Ringer's solution at a flow rate of 2 µL/min using a microinfusion pump (Harvard Apparatus 22, Holliston, MA, USA). In vivo probe recovery was determined by retrodialysis, which allowed for conversion of the measured dialysate concentrations into the actual unbound muscle concentrations. 7 Probe calibration was performed after a 30 min baseline sampling period and before dosage, and the dialysate was sampled at 30 min intervals before and after dosage. Blood samples were collected into lithiumheparinized tubes before dosage and at fixed time intervals up to 8 h after dosage and immediately centrifuged for 10 min at 3000 rpm and 4°C. Samples were analysed by validated modified high-performance liquid chromatography assays. 9, 11 The area under the curve (AUC) was calculated using the trapezoidal rule up to the last data point (C x ) and adding the extrapolated terminal area. Peak antibiotic concentrations (C max ) were obtained directly from the experimental data.
Results
Animal study
The free concentration of cefpodoxime measured in muscle was similar to that measured in lung tissue, and was predictably lower than total plasma concentrations ( Figure 1 ). Figure 2 show that the AUC values for the total plasma concentration of cefpodoxime and cefixime were generally similar (22.4 mg · h/L for cefpodoxime versus 25.6 mg · h/L for cefixime). As seen in previous studies that investigated plasma and free muscle concentrations of moxifloxacin and cefpirome, 12, 13 free muscle concentrations of each antibiotic were lower than total plasma concentrations. As shown in Table 1 , the tissue penetration of cefpodoxime was approximately two-fold higher than that of cefixime (tissue AUC 15.4 mg · h/L for cefpodoxime versus 7.3 · mg h/L for cefixime), resulting in higher peak free muscle concentrations of cefpodoxime (2.1 mg/L for cefpodoxime versus 0.9 mg/L for cefixime).
Clinical study
Discussion
These results show that the tissue penetration of cefpodoxime is substantially higher than that of cefixime, as demonstrated by its higher peak free tissue concentrations and AUC values. Therefore, basing predictions of antibacterial efficacy on total plasma concentrations could overestimate the free concentrations at the target site and possibly clinical efficacy. Clinical data provided by a study in paediatric acute otitis media support this hypothesis. 14 In that study, cefpodoxime was shown to be significantly more effective than cefixime in terms of clinical success rates (i.e. clinical cure plus improvement) (88% versus 73%, P <0.05), despite the fact that the in vitro spectrum of activity of each cephalosporin against the causative bacteria was similar. 5, 6 Thus, the findings of the current study may provide one explanation for treatment failures where the causative bacterial pathogens were susceptible to antibiotics in vitro.
As shown in a study reported by Kunin et al., 15 the degree of protein binding of an antibiotic is of substantial importance for direct antibiotic-bacteria interaction (the pharmacodynamics of antibiotics). In that model, based on the total plasma concentrations, high protein binding in vitro resulted in high MICs. It can therefore be concluded that high plasma protein binding is disadvantageous at the site of infection from a pharmacodynamic point of view.
Reliance on total plasma antibiotic concentrations in a PK/PD model for predicting clinical efficacy is common. Future clinical development of antibiotics should, however, take into account the concentrations of free antibiotics at the target sites to avoid the possibility of suboptimal concentrations and hence development of antibacterial resistance, and to establish sufficient and appropriate dosing regimens.
The results of this study are consistent with those of other studies in which microdialysis has been used to estimate free antibiotic concentrations at the target site of infection, 12, 13, 16 and suggest that concentrations of the free antibiotic at the target site may be a more appropriate parameter in a PK/PD model for predicting therapeutic efficacy.
The results in human volunteers show that the tissue penetration of cefpodoxime is greater than that of another oral cephalosporin, cefixime. This greater tissue penetration suggests favourable efficacy of cefpodoxime, and this is supported by clinical trial data. 14 The need for new approaches to clinical studies of antibiotics is emphasized in this article. Refinement of dosages and dosing schedules will benefit from a PK/PD-modelling approach involving free concentrations of antibiotics at target sites, especially since microdialysis now permits the accurate measurement of concentrations of free antibiotic in tissue. Bodies such as the US Food & Drug Administration are supporting such an approach and are watching developments closely. 17 
